4000-520-616
欢迎来到免疫在线！(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
产品库 品牌馆 现货促销 技术交流 新闻动态 联系我们
bdbiosciences
主营：主营：医疗设备、医疗耗材、实验仪器、抗体、试剂、诊断等产品
咨询热线电话
4000-520-616
公司首页 公司介绍 产品中心 新闻动态 联系方式 在线下单
当前位置： 首页 > 产品中心 > peptide > BD Biosciences/CD4 FITC/CD8 PE/CD3 PerCP with BD Trucount™ Tubes/20 µL/340401
商品详细BD Biosciences/CD4 FITC/CD8 PE/CD3 PerCP with BD Trucount™ Tubes/20 µL/340401
BD Biosciences/CD4 FITC/CD8 PE/CD3 PerCP with BD Trucount™ Tubes/20 µL/340401
BD Biosciences/CD4 FITC/CD8 PE/CD3 PerCP with BD Trucount™ Tubes/20 µL/340401
商品编号： 340401
品牌： bdbiosciences
市场价： ¥0.00
美元价： 0.00
产地： 美国(厂家直采)
公司：
产品分类： 多肽合成
公司分类： peptide
联系Q Q： 3392242852
电话号码： 4000-520-616
电子邮箱： info@ebiomall.com
立即询价
商品介绍
Product DetailsRecommended AssayReferences

Description

BD Tritest™ CD4 fluorescein isothiocyanate (FITC)/CD8 phycoerythrin (PE)/CD3 peridinin chlorophyll protein (PerCP) is a three-color direct immunofluorescence reagent used with BD Trucount™ absolute count tubes for identifying and determining absolute counts in cells/µL of mature human T lymphocytes (CD3+), helper/inducer (CD3+CD4++CD8+

Contents

SpecificityCloneFormatIsotypeEntrez Gene ID
CD4SK3 (also known as Leu3a)FITCIgG1, κ920
CD8SK1PEIgG1, κ925
CD3SK7 (also known as Leu-4)PerCPIgG1, κ916
Resources & Tools
SpectrumViewerDownload TDSDownload MSDS
Preparation and Storage

1. Store the reagent at 2–8°C. Do not use after the expiration date shown on the label.

2. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the reagent vial dry.

3. Store BD Trucount tubes in their original foil pouch at 2–25°C. To avoid potential condensation, open the pouch only after it has reached room temperature and carefully reseal the pouch immediately after removing a tube. Examine the desiccant each time you open the pouch. If the desiccant has turned from blue to lavender, discard the remaining tubes. Use tubes within 1 hour after removal from the foil pouch and do not use beyond the expiration date indicated on the packaging.

  1. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Peripheral Blood Lymphocytes; Tentative Guideline. Villanova, PA: National Committee for Clinical Laboratory Standard; 1992. NCCLS document H42-T.

  2. How to Define and Determine Reference Intervals in the Clinical Laboratory: Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; 1992. NCCLS document C28-A.

  3. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture: Approved Standard. Villanova, PA: National Committee for Clinical Laboratory Standards; 1991. NCCLS document H3-A3.

  4. Protection of Laboratory Workers from Infectious Disease Transmitted by Blood, Body Fluids, and Tissue: Tentative Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; NCCLS document M29-T2.

  5. Anderson P, Blue M-L, Morimoto C, Schlossman SF. Cross-linking of T3 (CD3) with T4 (CD4) enhances the proliferation of resting T lymphocytes. J Immunol. 1987;139:678-682.

  6. Angadi CV. Lack of Leu-3a epitope on T-helper (CD4) lymphocytes. J Clin Lab Anal. 1990;4:193-195.

  7. Antel J, Bania M, Noronha A, Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J Immunol. 1986;137:3436-3439.

  8. Bernard A, Boumsell L, Hill C. Joint report of the First International Workshop on Human Leucocyte Differentiation Antigens by the investigators of the participating laboratories: T2 protocol. In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman S, eds. Leukocyte Typing. 1984:25-60.

  9. Bishop GA, Hall BM, Duggin GG, Horvath JS, Sheil AGR, Tiller DJ. Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. Kidney Internat. 1986;29:708- 717.

  10. Brenner MB, McClean J, Dialynas DP, et al. Identification of a putative second T cell receptor. Nature. 1986;322:145-49.

  11. Centers for Disease Control. 1997 Revised guidelines for performing CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV). MMWR. 1997;46(No. RR-2):1-29.

  12. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.

  13. Clevers H, Alarcón B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol. 1988;6:629-662.

  14. Cohen SB, Weetman AP. Activated interstitial and intraepithelial thyroid lymphocytes in autoimmune thyroid disease. Acta Endocrinol. 1988;119:161-166.

  15. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-767.

  16. Eichmann K, Jönsson J-I, Falk I, Emmrich F. Effective activation of resting mouse T lymphocytes by cross-linking submitogenic concentrations of the T cell antigen receptor with either Lyt-2 or L3T4. Eur J Immunol. 1987;17:643-650.

  17. Evans RL, Wall DW, Platsoucas CD, et al. Thymus-dependent membrane antigens in man: inhibition of cellmediated lympholysis by monoclonal antibodies to the TH2 antigen. Proc Natl Acad Sci USA. 1981;78:544-548.

  18. Foucar K, Goeken JA. Clinical application of immunologic techniques to the diagnosis of lymphoproliferative and immunodeficiency disorders. Lab Med. 1982;13:403-413.

  19. Gallagher PF, Fazekas de St. Groth B, Miller JFAP. CD4 and CD8 molecules can physically associate with the same T-cell receptor. Proc Natl Acad Sci USA. 1989;86:10044-10048.

  20. Giorgi JV, Hultin LE. Lymphocyte subset alterations and immunophenotyping by flow cytometry in HIV disease. Clin Immunol Newslett. 1990;10:55-61.

  21. Giorgi JV. Lymphocyte subset measurements: significance in clinical medicine. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology; 1986:236-246.

  22. Gratama JW, Naipal A, Oljans P, et al. T-lymphocyte repopulation and differentiation after bone marrow transplantation: early shifts in the ratio between T4+ and T8+ T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood. 1984;63:1416-1423.

  23. Haynes BF. Summary of T-cell studies performed during the Second International Workshop and Conference on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human T Lymphocytes. New York, NY: Springer-Verlag; 1986;1:3-30.

  24. Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.

  25. Kan EAR, Wang CY, Wang LC, Evans RL. Noncovalently bonded subunits of 22 and 28 kd are rapidly internalized by T cells reacted with Anti–Leu-4 antibody. J Immunol. 1983;131:536-539.

  26. Knowles RW. Immunochemical analysis of the T-cell– specific antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human T Lymphocytes. New York, NY: Springer-Verlag; 1986;1:259- 288.

  27. Landay A, Ohlsson-Wilhelm B, Giorgi JV. Application of flow cytometry to the study of HIV infection. AIDS. 1990;4:479-497.

  28. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983;131:1789-1796.

  29. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986;47:333-348.

  30. Moebius U. Cluster report: CD8. In: Knapp W, Dörken B, Gilks WR, et al., eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1989:342-343.

  31. Nicholson J, Kidd P, Mandy F, Livnat D, Kagan J. Three-color supplement to the NIAID DAIDS guideline for flow cytometric immunophenotyping. Cytometry. 1996;26:227- 230.

  32. Nicholson JK, Browning SW, Orloff SL, McDougal JS. Inactivation of HIV-infected H9 cells in whole blood preparations by lysing/fixing reagents used in flow cytometry. J Immunol Methods. 1993;160:215-218.

  33. Nicholson JKA, Hubbard M, Jones BM. Use of CD45 fluorescence and side-scatter characteristics for gating lymphocytes when using the whole blood lysis procedure and flow cytometry. Cytometry. 1996;26: 16-21.

  34. Nicholson JKA, Jones BM, Hubbard M. CD4 T-lymphocyte determinations on whole blood specimens using a single-tube three-color assay. Cytometry. 1993;14:685-689.

  35. Nicholson JKA. Use of flow cytometry in the evaluation and diagnosis of primary and secondary immunodeficiency diseases. Arch Pathol Lab Med. 1989;113:598-605.

  36. Organizing Committee of the Fourth International Workshop on Human Leucocyte Differentiation Antigens. Appendix A: CD guide. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. 1989:1074-1093.

  37. Prince HE, Hirji K, Waldbeser LS, Plaeger-Marshall S, Kleinman S, Lanier LL. Influence of racial background on the distribution of T-cell subsets and Leu 11-positive lymphocytes in healthy blood donors. Diagn Immunol. 1985;3(1):33-37.

  38. Rudd CE, Burgess KE, Barber EK, Schlossman SF. Monoclonal antibodies to the CD4 and CD8 antigens precipitate variable amounts of CD4/CD8-associated p56lck activity. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:326-327.

  39. Schmidt R. Monoclonal antibodies for diagnosis of immunodeficiencies. Blut. 1989;59:200–206.

  40. Smolen JS, Chused TM, Leiserson WM, Reeves JP, Alling D, Steinberg AD. Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus: correlation with clinical features. Am J Med. 1982;72:783-790.

  41. van Dongen JJM, Krissansen GW, Wolvers-Tettero ILM, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 1988;71:603-612.

  42. Wolde-Mariam W, Peter JB. Recent diagnostic advances in cellular immunology. Diag Med. 1984;7:25-32.

  43. Wood GS, Warner NL, Warnke RA. Anti–Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol. 1983;131:212-216.

品牌介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。公司的服务对象包括医疗机构，生命科学研究所，临床实验室，工业单位和普通大众。BD has state-of-the-art facilities around the globe that provide an environment that enables our highly talented workforce to be the best at their professions. We hire associates who have a passion and commitment to advancing the world of health. We are always seeking great people to join our company on its journey to greatness.BDRat Granulocytes Pure RP-1  500ug550002BDMs Ig Kpa Lgt Chain FITC 187.1  500ug550007BDICC Fixation Buffer 100mL550011BDMs CD210 NALE 1B1.3a 500ug550019BDMs CD51 Pure RMV-7 100ug550026BDMs CD5 APC 53-7.3 100ug550037BDHu CD62E PE-Cy5 68-5H11 100Tst550041BDHu CD95 Pure EOS9.1  100ug550052BDHam IgG2 Kpa ItCl FITC B81-3 250ug550057BDMs Crry/p65 Pure 1F2 100ug550059BDMs IL-4 Recom Protein 10ug550068BDMs IL-2 Recom Protein 20ug550070BDHu IL-6 Recom Protein 10ug550072BDHu MIP-1 Bta PE D21-1351 100ug550082BDMs IgG1 PE A85-1 100ug550084BDHam IgG2 Kpa ItCl PE B81-3 100ug550086BDHu CD142 Pure HTF-1 100ug550254BDHu CD1d PE CD1d42 100Tst550256BDHu CD73 PE AD2 100Tst550258BDHu CD103 FITC Ber-ACT8 100Tst550260BDMs CD11c APC HL3 100ug550268BDMs CD72b/c Aloatg PE JY/93 100ug550270BDRat CD32 Pure D34-485 500ug550272BDRat CD32 NALE D34-485 500ug550274BDMs CD3e IHC Pure 145-2C11 1mL550277BDMs CD4 IHC Pure H129.19 1mL550280BDMs CD8a IHC Pure 53-6.7 1mL
公司介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包
品牌分类
HIV Reagent Kits Stem Cell Enumeration BD Multicheck™ Control Other Species Cell Separation Reagents BD Facsunt™ 控制套件 Single-Color Antibodies BD™ Stem Cell Control Kit Sample Multiplexing Reagents 纯化抗体
显示分类
联络我们
服务热线：4000-520-616
（限工作日9:00-18:00）
QQ ：1570468124
手机：18915418616
快速导航：
总部地址：
江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)
工作时间：周一至周五9:00~18:00
技术支持：
短信：18915418616
服务热线：
4000-520-616（全国）
☏  0512-67156496（苏州）
版权信息：
©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国
网站备案：
友情链接：
免责声明：
本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。
扫描二维码关注官方微信
获取最新促销及产品信息